Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUATTRO-II: CAPOXIRI plus bevacizumab versus FOLFOXIRI plus bevacizumab in first-line metastatic colorectal cancer
jRCTs041190072Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine, oxaliplatin, irinotecan, bevacizumab, fluorouracil and 1 more in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Nov 2019; status: completed.
02
Drugs
capecitabineoxaliplatinirinotecanbevacizumabfluorouracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCTs041190072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190072.